Advancing Muscle Disease Therapies
Developing innovative therapies to improve lives in muscle diseases.
Progress
Sarcomatrix is committed to developing Laminin-111 as a potential treatment for LAMA2-RD and is seeking funding to complete the pre-clinical work and advance the program to human studies as soon as reasonably possible.
Our small molecule α7β1 integrin activators have shown promise in mouse models stimulating muscle regeneration and may support many forms of muscular dystrophy including Duchenne, Beckers, Emery-Dreifuss, Facioscapulohumeral, Limb-Girdle and many forms of Congenital muscular dystrophy.
We Believe Polytherapy is Key
The future of gene and cell therapy for muscular dystrophy is exciting, and further advancements in these fields hold promise for the development of effective treatments for these debilitating diseases. Sarcomatrix fully supports development of gene and cell therapies and looks forward to the day the cure afflicted individuals. Until that day comes, we’re committed to polytherapy.
Polytherapy involves using multiple treatments in combination to achieve the best possible outcome. With the current options, a single treatment may not be enough to address all the symptoms and underlying causes of the disease.
What sets us apart is our promising platform of small molecules and proteins which may be used alone or in combination with exon skipping, gene editing or gene therapy technologies.
Our Platform & Pipeline
Progress Toward In-Human Trials
SarcoScreen™ is Sarcomatrix’s proprietary high-throughput screening platform, rapidly identifying and advancing innovative muscle-targeted therapies, driving accelerated innovation, diversified risk, and enabling valuable industry partnerships.
PROGRAM
Discovery
Preclinical
IND Enabling
Clinical Phase 1
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
Limb Girdle Muscular Dystrophy
Duchenne Muscular Dystrophy
Becker Muscular Dystrophy
MD Cardiac Myopathy
Congenital Muscular Dystrophy
Invest in a Better Tomorrow
Together, We Can Cure Muscle-Wasting Diseases
Your investment can help us accelerate pre-clinical research and move on to in-human trials so we can start offering treatments as soon as possible.
